Drug Recommendations, Presentations, Marketing Authorizations, and Board Appointments - Research Report on Johnson & Johnson, Lilly, Sanofi, GSK, and Pacira

NEW YORK, September 25, 2013 /PRNewswire/ --

Today, Analysts Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Eli Lilly and Company (NYSE: LLY), Sanofi (NYSE: SNY), GlaxoSmithKline plc (NYSE: GSK), and Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On September 20, 2013, Janssen-Cilag International NV (Janssen), a pharmaceutical company of Johnson & Johnson, announced that it has been granted a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval of INVOKANA in the European Union. According to the Company, INVOKANA has been recommended for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control. Jane Griffiths, Company Group Chairman of Janssen Europe, Middle-East, Africa, stated, "This positive opinion from the CHMP represents a major milestone in Johnson & Johnson's longstanding commitment to diabetes. If approved, INVOKANA will pave the way for Janssen as part of our goal to develop and provide new therapeutic options for adult patients with type 2 diabetes." The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

Eli Lilly and Company Research Report

On September 17, 2013, Eli Lilly and Company (Lilly) and Boehringer Ingelheim announced that the two companies will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, to be held from September 23, 2013 to September 27, 2013. The Company reported that eight clinical abstracts for empagliflozin and nine clinical and pre-clinical abstracts for linagliptin will be presented at the Annual Meeting. According to the Company, empagliflozin is a sodium glucose co-transporter 2 (SGLT2) inhibitor being investigated for the reduction of blood glucose levels in adults with type 2 diabetes (T2D), while linagliptin is an inhibitor of the enzyme, dipeptidyl peptidase-4 (DPP-4), which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) that are involved with regulating blood sugar. The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

--

Sanofi Research Report

On September 17, 2013, Sanofi and its subsidiary Genzyme announced that Lemtrada™ has been granted a marketing authorization by the European Commission. According to the Company, Lemtrada is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. David Meeker, M.D., President and CEO of Genzyme, stated, "The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis Patients." Meeker continued, "This is particularly exciting as the EU approval is the first for Lemtrada globally. We look forward to making these unique therapies available to MS patients very soon." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]

--

GlaxoSmithKline plc Research Report

On September 19, 2013, GlaxoSmithKline plc (GSK) and Theravance announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion recommending marketing authorization for fluticasone furoate/vilanterol (FF/VI) under the proposed brand name RELVAR ELLIPTA. According to GSK, RELVAR ELLIPTA is used in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate; and for the symptomatic treatment of adults with Chronic Obstructive Pulmonary Disease (COPD) with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy. Rick E Winningham, CEO of Theravance, commented, "This is another key milestone in over a decade of joint respiratory research and development between Theravance and GSK." The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

--

Pacira Pharmaceuticals, Inc. Research Report

On September 12, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the appointments of Mark A. Kronenfeld, M.D. and Dennis L. Winger to the Board of Directors. In addition, Pacira also announced that Luke Evnin, Managing Director at MPM Capital, and Fred Middleton, General Manager at Sanderling Ventures, will step down from the Board, effective September 30, 2013. Commenting on the board changes, Dave Stack, President, CEO, and Chairman of Pacira, said, "With their combined medical insight and deep expertise in developing and implementing successful commercial strategies, we are looking forward to working with them as we continue to execute on our own commercial strategy for EXPAREL and enter into the next stage of growth as a company. Additionally, we would like to recognize Luke and Fred for their innovative vision in forming the company in 2007 and thank them for their unwavering belief in our proprietary drug delivery technology and their thoughtful guidance throughout the development and successful launch of EXPAREL." The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c0aa_PCRX]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner